Inhibikase Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Share count: As of November 2, 2026, the company had 140,269,633 shares of common stock, $0.001 par value per share, outstanding.
- Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
- Exchange listing: Common stock trades on The Nasdaq Stock Market LLC under the symbol IKT (NASDAQ:IKT).
- Subsidiaries: The filing identifies two subsidiaries: IKT Securities Corporation, a Massachusetts corporation, and CorHepta Pharmaceuticals, Inc., a Delaware corporation.
- Lead candidate: The company disclosed that its lead product candidate, IKT-001, has received Orphan Drug Designation for the treatment of pulmonary arterial hypertension (PAH).
- Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
Inhibikase Therapeutics Reports Q3 2026 Position and IKT-001 Development Status
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) submitted its quarterly report for the period ended September 30, 2026, disclosing operational and corporate details as of the filing date. According to the filing, the company had 140,269,633 shares of common stock outstanding as of November 2, 2026. The registrant is incorporated in Delaware, with its principal executive offices located at 1000 N. West Street, Suite 1200, Wilmington, DE 19801.
The filing identifies the company's lead product candidate as IKT-001, which the company disclosed is being developed for the treatment of pulmonary arterial hypertension (PAH). According to the filing, IKT-001 has received Orphan Drug Designation for that indication. The company also disclosed its intent to conduct Phase 3 studies of IKT-001 in PAH across multiple countries and clinical sites, with interactions ongoing with the U.S. Food and Drug Administration (FDA). The filing notes these are forward-looking statements subject to risks, uncertainties, and assumptions that are difficult to predict, and the company stated it undertakes no obligation to revise or update such statements publicly except as required by law.
The filing further discloses two subsidiary entities: IKT Securities Corporation, a Massachusetts corporation, and CorHepta Pharmaceuticals, Inc., a Delaware corporation. The company reported that it uses its website and LinkedIn account to distribute material information and comply with Regulation FD obligations, though it specified that information accessible through those channels is not incorporated into the quarterly report.
What Was Disclosed
Inhibikase Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 140,269,633 shares outstanding as of November 2, 2026, its smaller reporting company and non-accelerated filer status, its two subsidiaries, and ongoing development of IKT-001 for PAH.



Please wait processing your request...